Scott Martin Vouri1,2,3, Mario Schootman4, Seth A Strope5, Stanley J Birge6, Margaret A Olsen6. 1. Department of Pharmacy Practice, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO, 63110, USA. scott.vouri@stlcop.edu. 2. St. Louis College of Pharmacy, Center for Health Outcomes Research and Education, St. Louis, MO, 63110, USA. scott.vouri@stlcop.edu. 3. Saint Louis University, College of Public Health and Social Justice, St. Louis, MO, 63110, USA. scott.vouri@stlcop.edu. 4. Saint Louis University, College of Public Health and Social Justice, St. Louis, MO, 63110, USA. 5. Baptist MD Anderson Cancer Center, Jacksonville, FL, 32207, USA. 6. Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
Abstract
BACKGROUND: Oral oxybutynin has been associated with the development of cognitive impairment. OBJECTIVE: The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) in older adults with documented cognitive impairment. METHODS: This is a population-based retrospective analysis of antimuscarinic new users aged ≥ 66 years from January 2008 to December 2011 (n = 42,886) using a 5% random sample of Medicare claims linked with Part D data. Cognitive impairment was defined as a diagnosis of mild cognitive impairment, dementia, use of antidementia medication, and memory loss/drug-induced cognitive conditions in the year prior to the initial antimuscarinic claim. We used multivariable generalized linear models to assess indicators of cognitive impairment associated with initiation of oral oxybutynin versus other antimuscarinics after adjusting for comorbid conditions. RESULTS: In total, 33% received oral oxybutynin as initial therapy. Cognitive impairment was documented in 10,259 (23.9%) patients prior to antimuscarinic therapy. Patients with cognitive impairment were 5% more likely to initiate another antimuscarinic versus oral oxybutynin (relative risk [RR] 1.05; 95% confidence interval [CI] 1.03-1.06). The proportion of patients with cognitive impairment initiated on oral oxybutynin increased from 24.1% in 2008 to 41.1% in 2011. The total cost of oral oxybutynin, in $US, year 2011 values, decreased by 10.5%, whereas the total cost of other antimuscarinics increased by 50.3% from 2008 to 2011. CONCLUSION: Our findings suggest opportunities for quality improvement of antimuscarinic prescribing in older adults, but this may be hampered by cost and formulary restrictions.
BACKGROUND: Oral oxybutynin has been associated with the development of cognitive impairment. OBJECTIVE: The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) in older adults with documented cognitive impairment. METHODS: This is a population-based retrospective analysis of antimuscarinic new users aged ≥ 66 years from January 2008 to December 2011 (n = 42,886) using a 5% random sample of Medicare claims linked with Part D data. Cognitive impairment was defined as a diagnosis of mild cognitive impairment, dementia, use of antidementia medication, and memory loss/drug-induced cognitive conditions in the year prior to the initial antimuscarinic claim. We used multivariable generalized linear models to assess indicators of cognitive impairment associated with initiation of oral oxybutynin versus other antimuscarinics after adjusting for comorbid conditions. RESULTS: In total, 33% received oral oxybutynin as initial therapy. Cognitive impairment was documented in 10,259 (23.9%) patients prior to antimuscarinic therapy. Patients with cognitive impairment were 5% more likely to initiate another antimuscarinic versus oral oxybutynin (relative risk [RR] 1.05; 95% confidence interval [CI] 1.03-1.06). The proportion of patients with cognitive impairment initiated on oral oxybutynin increased from 24.1% in 2008 to 41.1% in 2011. The total cost of oral oxybutynin, in $US, year 2011 values, decreased by 10.5%, whereas the total cost of other antimuscarinics increased by 50.3% from 2008 to 2011. CONCLUSION: Our findings suggest opportunities for quality improvement of antimuscarinic prescribing in older adults, but this may be hampered by cost and formulary restrictions.
Authors: Gary G Kay; Paul Maruff; David Scholfield; Bimal Malhotra; Laurence Whelan; Amanda Darekar; Diane L Martire Journal: Postgrad Med Date: 2012-05 Impact factor: 3.840
Authors: Lisa M Kalisch Ellett; Nicole L Pratt; Emmae N Ramsay; John D Barratt; Elizabeth E Roughead Journal: J Am Geriatr Soc Date: 2014-10-03 Impact factor: 5.562
Authors: Scott Martin Vouri; Mario Schootman; Seth A Strope; Hong Xian; Margaret A Olsen Journal: Arch Gerontol Geriatr Date: 2018-09-22 Impact factor: 3.250
Authors: Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu Journal: J Gen Intern Med Date: 2020-02-05 Impact factor: 5.128
Authors: Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu Journal: Curr Med Res Opin Date: 2021-05-13 Impact factor: 2.705
Authors: Douglas Barthold; Zachary A Marcum; Shelly L Gray; Julie Zissimopoulos Journal: Pharmacoepidemiol Drug Saf Date: 2020-08-27 Impact factor: 2.732
Authors: L P Dantas; A R C C Forte; B C Lima; C N S Sousa; E C Vasconcelos; P H C Lessa; R F Vieira; M C A Patrocínio; S M M Vasconcelos Journal: Braz J Med Biol Res Date: 2022-01-25 Impact factor: 2.590